Collaboration between suppliers and developers, as well as viral vector manufacturing simplification, are becoming critical to CGT's commercial future, says Brandon Pence of FUJIFILM Biosciences.
Brandon Pence
Advertisement
Brandon Pence is president and chief operating officer of FUJIFILM Biosciences
Articles by Brandon Pence
Brandon Pence, FUJIFILM Biosciences' president and chief operating officer, identifies cell consistency and viral vector capsid fill ratios as the 2 most critical unresolved hurdles in CGT manufacturing scale-up.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Alvotech, Advanz Submit First Eylea 8 mg Biosimilar Bid
2
Lilly's Mirikizumab (Omvoh) Hits New IBD Remission Goals
3
FDA Expands Anktiva Approval to Papillary-Only BCG-Unresponsive Bladder Cancer
4
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
5